您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > LLY-283
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LLY-283
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LLY-283图片
CAS NO:2040291-27-6
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW) 342.36
Formula C17H18N4O4
CAS No. 2040291-27-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 10 mM
Water: N/A
Ethanol: N/A
Chemical Name (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(R)-hydroxy(phenyl)methyl]oxolane-3,4-diol
Synonyms LLY-283; LM5179; LLY283; LM-5179; LLY 283; LM 5179
SMILES Code O[C@H]1[C@H](N2C=CC3=C(N)N=CN=C32)O[C@H]([C@H](O)C4=CC=CC=C4)[C@H]1O
实验参考方法
In Vitro

In vitro activity: LLY-283 is the first potent and selective SAM-competitive chemical probe for PRMT5 (protein arginine methyltransferase 5). In a biochemical assay, LLY-283 inhibits the PRMT5 enzyme activity with an IC50 of 20 nM for methylation of an H4R3 derived peptide substrate, it exhibits more than 100-fold selectivity for PRMT5 than other histone methyltransferases and non-epigenetic targets. PRMTs binds to the lysine or arginine residues of substrate proteins via the substrate binding groove and SAM via the cofactor binding site. These two binding sites are linked by a narrow hydrophobic channel that brings the substrate and cofactor in close proximity to allow the transfer of the methyl group from the cofactor SAM to a lysine or arginine residue via an SN2 transition state.


Kinase Assay: LLY-283 inhibits the methylation of SmBB′ with an IC50 of 25 nM in MCF7 cells and also affects MDM4 splicing with an IC50 of 40 nM in A375 cells


Cell Assay: LLY-283, the first potent and selective SAM-competitive chemical probe for PRMT5 was recently discovered. LLY-283 potently inhibited PRMT5 with an IC50 of 20 nM in a biochemical assay. It was>100-fold selective for PRMT5 over other methyltransferases and nonepigenetic targets. In cellular assays, it inhibited the methylation of SmBB′ with an IC50 of 25 nM in MCF7 cells and also affected MDM4 splicing with an IC50 of 40 nM in A375 cells.

In VivoLLY-283 (20 mg/kg; p.o., QD (once a day)) causes a significant inhibition on tumor growth in mice bearing A375 cells after treatment for 28 days
Animal modelMice bearing A375 tumor
Formulation & Dosage20 mg/kg; p.o.
ReferencesChem Rev. 2018 Feb 14; 118(3): 989–1068; -probes/LLY-283